Anti-CD73 antibody activates human B cells, enhances humoral responses and induces redistribution of B cells in patients with cancer
Richard A. Miller(Collaborative Drug Discovery (United States)), Stephen B. Willingham(Silvus Technologies (United States))
Cited by 24
Related Papers
The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors
|Proceedings of the National Academy of Sciences|2012|1.6k
Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors
|Science Translational Medicine|2017|427
Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma
|Proceedings of the National Academy of Sciences|2012|256
Anti-KIT monoclonal antibody inhibits imatinib-resistant gastrointestinal stromal tumor growth
|Proceedings of the National Academy of Sciences|2013|55